tirzepatide surmount-1 weight loss percent nejm 2022 SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions In the SURMOUNT-1 trial (published
Description
Nevertheless, the pharmacokinetics of liraglutide, including its distribution to the brain, has not been fully characterized
The drug works by mimicking certain hormones in the body that influence insulin release and appetite control
Steadier weight loss
a 52-week, phase 3b, randomized, double-blind, open-label study &mdash
